Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. is a pharmaceutical company that develops and markets prescription products. The company's business model inherently involves animal testing as part of the drug development and regulatory approval process required by the FDA and other global health authorities. This reliance on animal research places its operations within the scope of commercial animal exploitation.

In 2024, a federal court ordered the removal of over 4,000 beagles from a Cumberland, Virginia breeding facility operated by Envigo RMS LLC, a company then owned by Inotiv, which was Cumberland Pharmaceuticals' primary contract research organization (CRO) partner for preclinical testing. The U.S. Department of Justice filed a lawsuit alleging egregious violations of the Animal Welfare Act at this facility, which supplied dogs for research. The DOJ's complaint documented systemic animal welfare failures, including inadequate veterinary care, unsanitary conditions, and preventable animal suffering and deaths. This enforcement action resulted in a historic $35 million settlement and permanent prohibition against Envigo RMS LLC from engaging in further Animal Welfare Act violations.

While Cumberland Pharmaceuticals itself is not a breeder, its supply chain was directly linked to this large-scale commercial breeding operation cited for severe animal welfare violations. The company's reliance on animal testing and its partnership with a CRO implicated in such a significant case of animal cruelty demonstrates its embedded role in an industry system that exploits animals at scale.